Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus JAIMIESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus JAIMIESS.
ENSKYCE vs JAIMIESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Norepinephrine and dopamine reuptake inhibitor; also weakly inhibits serotonin reuptake. Enhances synaptic concentrations of norepinephrine and dopamine, particularly in prefrontal cortex.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
100 mg orally once daily with food.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in severe impairment).
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Primarily renal excretion as unchanged drug (approximately 70%) with the remainder as inactive metabolites; less than 10% excreted in feces.
Category C
Category C
Oral Contraceptive
Oral Contraceptive, Combined